Raymond James reiterates Humana stock rating on Q3 beat

Humana reported Q3 2026 revenue of $41.2B, above the $40.9B Street estimate, and adjusted EPS of -$0.70 versus expectations of -$1.00; its 93.7% insurance medical loss ratio also beat the 94.2% estimate. The company raised its full-year adjusted EPS minimum to $9.50 from $9.00, while CenterWell adjusted EBIT of $291M missed Raymond James’ $478M estimate and the company still posted an adjusted pre-tax loss of $104M. Raymond James reiterated Outperform with a $520 price target.

Analysis

The key quality question is whether the insurance improvement is repeatable, not whether the quarter beat estimates. Favorable prior-period development contributed only modestly to the reported MLR, so the beat appears less dependent on reserve releases than the prior-year comparison might suggest; however, the article does not explain the remaining drivers. Verify utilization, membership mix, and pricing adequacy before treating the result as a durable margin inflection. CenterWell’s EBIT shortfall is a separate offset: persistent weakness there could dilute the benefit of insurance recovery and challenge the broader earnings-restoration narrative.

The raised earnings floor supports the bull case, but HUM has already rallied sharply. Near term, the risk is that further good news is needed just to sustain momentum; analyst targets cited in the article are not independent evidence of fair value. Over 1–3 months, watch management’s explanation of the insurance MLR, enrollment/mix trends, and any 2027 Medicare Advantage bid or benefit changes. Over 6–18 months, rate adequacy and medical-cost trend will determine whether improved insurance economics can persist; policy or utilization surprises could reverse the recovery. A useful competitive read-through is whether peers such as UnitedHealth, CVS, Elevance, and Centene report similar cost trends—broad improvement would reduce HUM-specific differentiation, while HUM-only strength would support the turnaround thesis.

Key Decisions for Investors

• Do not chase the post-rally move solely on the quarterly beat. Existing holders can retain a core position but consider trimming into strength if subsequent updates fail to validate the insurance margin improvement.
• Treat HUM as a catalyst-driven watch rather than a high-conviction fresh long until management discloses the drivers of the MLR beat and CenterWell’s recovery path. Reassess after the next results and relevant Medicare Advantage rate/bid updates.
• If protecting a meaningful existing long, evaluate a defined-risk put spread covering the next earnings window; check implied volatility and cost first, as the supplied information is insufficient to price the hedge.
• Falsification: reduce the turnaround thesis if insurance MLR worsens materially versus management’s outlook, the earnings floor is cut, or CenterWell weakness persists. Confirmation would require sustained insurance performance without reliance on favorable prior-period development.